Shares Magazine
0.45p+0.00 (+0.00%)17 Apr 2025, 15:25
Jump to:
Oxford Biodynamics PLC Fundamentals
| Company Name | Oxford Biodynamics PLC | Last Updated | 2025-04-17 |
|---|---|---|---|
| Industry | Biotechnology | Sector | Healthcare |
| Shares in Issue | 1.958 bn | Market Cap | £8.81 m |
| PE Ratio | 0.00 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -£0.05 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0.4741 | Debt Equity Ratio | 1.0771 |
| Asset Equity Ratio | 2.7783 | Cash Equity Ratio | 0.6487 |
| Quick Ratio | 1.6434 | Current Ratio | 1.97 |
| Price To Book Value | 2.0214 | ROCE | 0 |
Oxford Biodynamics PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Oxford Biodynamics PLC Company Financials
| Assets | 2024 | 2023 | 2022 |
|---|---|---|---|
| Tangible Assets | £5.71 m | £7.00 m | £6.98 m |
| Intangible Assets | £1.35 m | £1.91 m | £1.60 m |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | £7.06 m | £8.96 m | £8.58 m |
| Stocks | £321,000.00 | £274,000.00 | £337,000.00 |
| Debtors | £1.39 m | £957,000.00 | £509,000.00 |
| Cash & Equivalents | £2.83 m | £5.25 m | £999,000.00 |
| Other Assets | 0 | 0 | 0 |
| Total Assets | £12.11 m | £16.13 m | £11.34 m |
| Liabilities | 2024 | 2023 | 2022 |
|---|---|---|---|
| Creditors within 1 year | £2.56 m | £4.00 m | £2.91 m |
| Creditors after 1 year | £5.19 m | £6.07 m | £5.84 m |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £7.75 m | £10.07 m | £8.76 m |
| Net assets | £4.36 m | £6.05 m | £2.59 m |
| Equity | 2024 | 2023 | 2022 |
|---|---|---|---|
| Called up share capital | £3.12 m | £2.02 m | £1.00 m |
| Share Premium | £40.15 m | £32.14 m | £19.02 m |
| Profit / Loss | -£11.96 m | -£11.41 m | -£7.57 m |
| Other Equity | £4.36 m | £6.05 m | £2.59 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | £4.36 m | £6.05 m | £2.59 m |
| Ratios | 2024 | 2023 | 2022 |
|---|---|---|---|
| Debt Ratio | £0.52 | £0.48 | £0.68 |
| Debt-to-Equity | £1.08 | £0.93 | £2.09 |
| Assets / Equity | 2.7783 | 2.7783 | 2.7783 |
| Cash / Equity | 0.6487 | 0.6487 | 0.6487 |
| EPS | -£0.04 | -£0.07 | -£0.07 |
| Cash Flow | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash from operating activities | -£10.17 m | -£8.29 m | -£5.18 m |
| Cashflow before financing | -£1.92 m | £4.91 m | -£2.62 m |
| Increase in Cash | -£3.40 m | £4.29 m | -£1.36 m |
| Income | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | £636,000.00 | £510,000.00 | £154,000.00 |
| Cost of sales | £347,000.00 | £244,000.00 | £38,000.00 |
| Gross Profit | £289,000.00 | £266,000.00 | £116,000.00 |
| Operating Profit | -£12.89 m | -£10.17 m | -£8.60 m |
| Pre-Tax profit | -£11.96 m | -£11.41 m | -£7.57 m |
Oxford Biodynamics PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | Oxford BioDynamics PLC is a biotechnology company engaged in developing and commercializing precision clinical diagnostic tests for life-changing diseases. It has two commercially available products: the EpiSwitch PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test) blood tests. The tests are based on the company's proprietary 3D genomic biomarker platform, EpiSwitch which enables screening, evaluation, validation, and monitoring of biomarkers. In addition, the company offers, EpiSwitch Explorer Array Kit for 3D genome profiling. It is also developing new tests in the areas of oncology, neurology, inflammation, hepatology, and animal health. Geographically, it derives key revenue from the United States of America. |
| Latest Interim Date | 18 Jun 2024 |
| Latest Fiscal Year End Date | 28 Feb 2025 |
Oxford Biodynamics PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2025-03-03 | Mr. Iain Gladstone Ross | Executive Director,Chairman |
| 2019-03-13 | Mr. David Jefferys Williams | Non-Executive Director,Chairman |
| 2025-03-05 | Dr. David Mark Anthony Holbrook | Non-Executive Director |
| 2025-04-10 | Mr. Peter Eric Presland | Non-Executive Director |
| 2020-12-30 | Mr. Christian Gurth Hoyer Millar | Executive Director |
| 2025-03-03 | Dr. Alexandre Akoulitchev | Executive Director,Chief Scientific Officer |
| 2025-02-03 | Mr. Stephen Charles Diggle | Non-Executive Director |
| 2025-04-02 | Mr. Paul Leslie Stockdale | Executive Director,Chief Financial Officer |
| 2020-12-14 | Mr. Peter Pack | Non-Executive Director,Chairman |
| 2024-12-16 | Dr. Jon Anthony Joseph Burrows | Executive Director,Group Chief Executive Officer |
| 2025-03-17 | Mr. Matthew Anthony Wakefield | Non-Executive Director,Deputy Chairman |
Oxford Biodynamics PLC Contact Details
| Company Name | Oxford BioDynamics PLC |
|---|---|
| Address | 26 Beaumont Street, Oxford, OX1 2NP |
| Telephone | +44 1865518910 |
| Website | https://www.oxfordbiodynamics.com |
Oxford Biodynamics PLC Advisors
| Stockbroker | Shore Capital Stockbrokers Ltd |
|---|---|
| Phone | +44 2074084050 |
| Fax | +44 2074084091 |
| Bank | HSBC Bank PLC |
|---|
| Solicitor | Mayer Brown International LLP |
|---|---|
| Phone | +44 2031303000 |
| Fax | +44 2031303001 |
| Auditor | KPMG |
|---|---|
| Phone | +44 1189642000 |
| Fax | +44 1189642222 |
| Registrar | Capita Asset Services |
|---|---|
| Phone | +44 8716640300 |
| Fax | +44 2086392342 |
| Financial PR Adviser | FTI Consulting Inc |
|---|---|
| Phone | +44 2037271000 |
| Fax | +44 2037271007 |
| Nominated Adviser | Stifel Nicolaus Europe Ltd |
|---|---|
| Phone | +44 2077107600 |
| Fax | +44 2077107609 |
| Stockbroker | Stifel Nicolaus Europe Ltd |
|---|---|
| Phone | +44 2077107600 |
| Fax | +44 2077107609 |
| Financial PR Adviser | Consilium Strategic Communications |
|---|---|
| Phone | +44 2037095700 |
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Dunelm Group PLC | 1,074.00 | 13.29 |
| Asos PLC | 313.50 | 6.63 |
| Rentokil Initial PLC | 350.00 | 5.01 |
| Sainsbury (J) PLC | 256.80 | 3.55 |
| Dr. Martens PLC | 52.80 | 3.53 |
| Pershing Square Holdings LTD | 3,414.00 | 3.45 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Dowlais Group PLC | 51.40 | -6.03 |
| Fresnillo PLC | 1,021.00 | -5.55 |
| Jupiter Fund Management PLC | 69.30 | -5.07 |
| Goodwin PLC | 6,780.00 | -4.51 |
| Spectris PLC | 1,987.00 | -4.38 |
| Twentyfour Income Fund Limited | 108.60 | -3.89 |
Risers/fallers data from previous trading day. Today's data available from 8:15am.